ATE521695T1 - Zirkuläres dna-molekül mit einem konditionalen replikationsursprung, verfahren zur herstellung davon und ihre verwendung in der gentherapie - Google Patents
Zirkuläres dna-molekül mit einem konditionalen replikationsursprung, verfahren zur herstellung davon und ihre verwendung in der gentherapieInfo
- Publication number
- ATE521695T1 ATE521695T1 AT03777599T AT03777599T ATE521695T1 AT E521695 T1 ATE521695 T1 AT E521695T1 AT 03777599 T AT03777599 T AT 03777599T AT 03777599 T AT03777599 T AT 03777599T AT E521695 T1 ATE521695 T1 AT E521695T1
- Authority
- AT
- Austria
- Prior art keywords
- gene therapy
- dna molecule
- circular dna
- producing
- replication origin
- Prior art date
Links
- 238000001415 gene therapy Methods 0.000 title abstract 3
- 108020004638 Circular DNA Proteins 0.000 title abstract 2
- 102000053602 DNA Human genes 0.000 title abstract 2
- 108020005091 Replication Origin Proteins 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 230000010076 replication Effects 0.000 abstract 2
- 108020004414 DNA Proteins 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000007523 nucleic acids Chemical group 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
- C07K14/501—Fibroblast growth factor [FGF] acidic FGF [aFGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
- C12N15/69—Increasing the copy number of the vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/268,948 US7279313B2 (en) | 1995-09-15 | 2002-10-11 | Circular DNA molecule having a conditional origin of replication, process for their preparation and their use in gene therapy |
PCT/US2003/032512 WO2004033664A2 (en) | 2002-10-11 | 2003-10-14 | Circular dna molecule having a conditional origin of replication, process for their preparation and their use in gene therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE521695T1 true ATE521695T1 (de) | 2011-09-15 |
Family
ID=32092417
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT03777599T ATE521695T1 (de) | 2002-10-11 | 2003-10-14 | Zirkuläres dna-molekül mit einem konditionalen replikationsursprung, verfahren zur herstellung davon und ihre verwendung in der gentherapie |
Country Status (22)
Country | Link |
---|---|
US (3) | US7279313B2 (de) |
EP (1) | EP1549735B1 (de) |
JP (2) | JP4522861B2 (de) |
KR (1) | KR101323542B1 (de) |
CN (2) | CN101182534B (de) |
AT (1) | ATE521695T1 (de) |
AU (2) | AU2003287078B2 (de) |
BR (1) | BR0314512A (de) |
CA (1) | CA2501851C (de) |
CY (1) | CY1112110T1 (de) |
DK (1) | DK1549735T3 (de) |
ES (1) | ES2372599T3 (de) |
HK (2) | HK1082761B (de) |
IL (1) | IL167706A (de) |
MX (1) | MXPA05003857A (de) |
NO (1) | NO333932B1 (de) |
NZ (2) | NZ566205A (de) |
PT (1) | PT1549735E (de) |
RU (1) | RU2307870C2 (de) |
SI (1) | SI1549735T1 (de) |
WO (1) | WO2004033664A2 (de) |
ZA (1) | ZA200503039B (de) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7038026B2 (en) | 2000-05-26 | 2006-05-02 | Centelion | Purification of a triple heli formation with an immobilized oligonucleotide |
FR2738842B1 (fr) * | 1995-09-15 | 1997-10-31 | Rhone Poulenc Rorer Sa | Molecule d'adn circulaire a origine de replication conditionnelle, leur procede de preparation et leur utilisation en therapie genique |
US7279313B2 (en) * | 1995-09-15 | 2007-10-09 | Centelion | Circular DNA molecule having a conditional origin of replication, process for their preparation and their use in gene therapy |
FR2822476B1 (fr) * | 2001-03-23 | 2004-04-02 | Aventis Pharma Sa | Procedes de purification et de detection de sequences cibles d'adn double brin par interaction triple helice |
EP2246413A3 (de) | 2004-04-19 | 2011-10-26 | Centelion | Verfahren zur Herstellung einer Plasmid-DNA in pharmazeutischer Qualität |
JP4581851B2 (ja) * | 2004-07-27 | 2010-11-17 | セイコーエプソン株式会社 | 電気光学装置の駆動回路及び駆動方法、電気光学装置並びに電子機器 |
FR2920158B1 (fr) * | 2007-08-24 | 2010-03-12 | Centre Nat Rech Scient | Production de plasmides et expression de proteines recombinantes dans des cellules cultivees sans antibiotiques |
EP2221066A1 (de) | 2009-02-18 | 2010-08-25 | Sanofi-Aventis | Verwendung des VgII3-Aktivitätsmodulators zur Modulierung von Adipogenese |
EP2471909A1 (de) * | 2010-12-30 | 2012-07-04 | SIRION BIOTECH GmbH | Nukleinsäuremoleküle zur Herstellung adenoviraler Vektoren |
JP5863338B2 (ja) * | 2011-08-25 | 2016-02-16 | 株式会社東芝 | プラスミド型ベクター、遺伝子プロモーター活性の検出方法、及びアッセイキット |
US9550998B2 (en) | 2012-08-29 | 2017-01-24 | Nature Technology Corporation | DNA plasmids with improved expression |
WO2014077863A1 (en) | 2012-11-19 | 2014-05-22 | Nature Technology Corporation | Replicative minicircle vectors with improved expression |
EP3044318B1 (de) | 2013-09-13 | 2019-05-01 | California Institute of Technology | Selektive rückgewinnung |
CN107002069A (zh) * | 2014-11-18 | 2017-08-01 | 国立研究开发法人科学技术振兴机构 | 环状dna的扩增方法 |
US10086089B2 (en) | 2015-09-18 | 2018-10-02 | DNARx | Systems and methods for nucleic acid expression in vivo |
US11499165B2 (en) | 2015-12-11 | 2022-11-15 | California Institute Of Technology | Targeting peptides for directing adeno-associated viruses (AAVs) |
CA3057320A1 (en) * | 2017-03-23 | 2018-09-27 | DNARx | Systems and methods for nucleic acid expression in vivo |
ES2950736T3 (es) | 2018-03-21 | 2023-10-13 | Aldevron L L C | Vectores de nanoplásmidos virales y no virales con una producción mejorada |
CA3106822C (en) * | 2018-07-30 | 2023-10-10 | OriCiro Genomics, Inc. | Method for editing dna in cell-free system |
JP2022518200A (ja) * | 2019-01-18 | 2022-03-14 | ヤンセン バイオテツク,インコーポレーテツド | 非抗生物質選択マーカーとしてのβ-ガラクトシダーゼαペプチド及びその使用 |
EP4419675A1 (de) * | 2021-10-18 | 2024-08-28 | ModernaTX, Inc. | Markerlose dna-produktion |
WO2023241567A1 (zh) * | 2022-06-13 | 2023-12-21 | 南京金斯瑞生物科技有限公司 | 一种可提高无筛选标签质粒制备效率的野生型-突变体π蛋白切换表达系统 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4190495A (en) * | 1976-09-27 | 1980-02-26 | Research Corporation | Modified microorganisms and method of preparing and using same |
US4727028A (en) * | 1981-06-22 | 1988-02-23 | Eli Lilly And Company | Recombinant DNA cloning vectors and the eukaryotic and prokaryotic transformants thereof |
US4654307A (en) | 1983-02-17 | 1987-03-31 | The Research Foundation Of State University Of New York | Novel bacteria containing a plasmid having a tRNA code |
US4761367A (en) | 1984-11-07 | 1988-08-02 | The University Of North Carolina At Chapel Hill | Vectors suitable for detection of eukaryotic DNA regulatory sequences |
US5859208A (en) | 1988-07-06 | 1999-01-12 | Fiddes; John C. | Human basic fibroblast growth factor analog |
US5198343A (en) * | 1986-08-05 | 1993-03-30 | Transgene, S.A. | Method for expressing a heterologous protein in a dapD- mutant of E. coli and the strain obtained |
US5510099A (en) | 1987-05-01 | 1996-04-23 | Stratagene | Mutagenesis testing using transgenic non-human animals carrying test DNA sequences |
RU2107725C1 (ru) * | 1989-02-24 | 1998-03-27 | Монсанто Компани | Способ модификации фрагмента днк, кодирующего инсектицидный белок bacillus thuringiensis, фрагмент днк, кодирующий инсектицидный белок bacillus thuringiensis (варианты), фрагмент днк, содержащий структурный ген, кодирующий инсектицидный белок (варианты), и фрагмент днк, содержащий структурный ген, кодирующий слитый белок |
US5693622A (en) | 1989-03-21 | 1997-12-02 | Vical Incorporated | Expression of exogenous polynucleotide sequences cardiac muscle of a mammal |
US5512463A (en) * | 1991-04-26 | 1996-04-30 | Eli Lilly And Company | Enzymatic inverse polymerase chain reaction library mutagenesis |
TW201794B (de) * | 1991-05-03 | 1993-03-11 | American Cyanamid Co | |
US5714323A (en) | 1991-08-30 | 1998-02-03 | The University Of Medecine And Dentistry Of New Jersey | Over expression of single-stranded molecules |
US5444149A (en) | 1992-05-11 | 1995-08-22 | Duke University | Methods and compositions useful in the recognition, binding and expression of ribonucleic acids involved in cell growth, neoplasia and immunoregulation |
US5434065A (en) | 1993-05-06 | 1995-07-18 | President And Fellows Of Harvard College | In vivo selection of microbial virulence genes |
CA2169292C (en) | 1993-08-12 | 2010-11-23 | E. Edward Baetge | Improved compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules |
US5679647A (en) * | 1993-08-26 | 1997-10-21 | The Regents Of The University Of California | Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides |
US5700657A (en) | 1993-12-13 | 1997-12-23 | Genzyme Corporation | Vectors and vector systems including genes encoding tumor suppressor proteins and producer cells transformed thereby |
IL109558A (en) | 1994-05-04 | 2004-08-31 | Yissum Res Dev Co | DNA structures Derived from the SV40 virus that include DNA sequences External |
WO1996001899A1 (en) | 1994-07-08 | 1996-01-25 | Schering Corporation | METHOD FOR IDENTIFYING NUCLEIC ACIDS ENCODING c-fos PROMOTER ACTIVATING PROTEINS |
DE4428402A1 (de) | 1994-08-11 | 1996-02-15 | Boehringer Mannheim Gmbh | Gentherapeutisches Verfahren unter Verwendung von DNA-Vektoren ohne Selektionsmarker-Gen |
US5792647A (en) | 1995-02-13 | 1998-08-11 | The Johns Hopkins University | Bacterial catabolism of chitin |
US6825012B2 (en) * | 1995-02-23 | 2004-11-30 | Gencell S.A. | DNA molecules, preparation and use in gene therapy |
US6254874B1 (en) | 1995-04-13 | 2001-07-03 | President And Fellows Of Harvard College | Attenuated auxotrophic microorganisms having a combination of non-attenuating mutations and method for making same |
JP3530676B2 (ja) * | 1995-04-26 | 2004-05-24 | キヤノン株式会社 | 光受容部材の製造方法、該光受容部材、該光受容部材を有する電子写真装置及び該光受容部材を用いた電子写真プロセス |
US7279313B2 (en) * | 1995-09-15 | 2007-10-09 | Centelion | Circular DNA molecule having a conditional origin of replication, process for their preparation and their use in gene therapy |
US7364894B2 (en) * | 1995-09-15 | 2008-04-29 | Centelion | Circular DNA molecule having a conditional origin of replication, process for their preparation and their use in gene therapy |
FR2738842B1 (fr) * | 1995-09-15 | 1997-10-31 | Rhone Poulenc Rorer Sa | Molecule d'adn circulaire a origine de replication conditionnelle, leur procede de preparation et leur utilisation en therapie genique |
US5851808A (en) | 1997-02-28 | 1998-12-22 | Baylor College Of Medicine | Rapid subcloning using site-specific recombination |
US5874259A (en) | 1997-11-21 | 1999-02-23 | Wisconsin Alumni Research Foundation | Conditionally amplifiable BAC vector |
NZ543717A (en) | 2003-06-05 | 2008-06-30 | Centelion | Administration of a plasmid encoding a fibroblast growth factor (FGF), wherein VEGF-A factor expression is not induced in the myocardial or skeletal muscle to treat myocardial or skeletal angiogenic disorders or defects associated with hypercholesterolemia or diabetes |
-
2002
- 2002-10-11 US US10/268,948 patent/US7279313B2/en not_active Expired - Fee Related
-
2003
- 2003-10-14 PT PT03777599T patent/PT1549735E/pt unknown
- 2003-10-14 CN CN2007101620919A patent/CN101182534B/zh not_active Expired - Fee Related
- 2003-10-14 JP JP2004543780A patent/JP4522861B2/ja not_active Expired - Fee Related
- 2003-10-14 AT AT03777599T patent/ATE521695T1/de active
- 2003-10-14 ES ES03777599T patent/ES2372599T3/es not_active Expired - Lifetime
- 2003-10-14 KR KR1020057006228A patent/KR101323542B1/ko not_active IP Right Cessation
- 2003-10-14 CN CNB2003801041846A patent/CN100491521C/zh not_active Expired - Fee Related
- 2003-10-14 RU RU2005114367/13A patent/RU2307870C2/ru not_active IP Right Cessation
- 2003-10-14 DK DK03777599.6T patent/DK1549735T3/da active
- 2003-10-14 EP EP03777599A patent/EP1549735B1/de not_active Expired - Lifetime
- 2003-10-14 CA CA2501851A patent/CA2501851C/en not_active Expired - Fee Related
- 2003-10-14 WO PCT/US2003/032512 patent/WO2004033664A2/en active Application Filing
- 2003-10-14 SI SI200332068T patent/SI1549735T1/sl unknown
- 2003-10-14 AU AU2003287078A patent/AU2003287078B2/en not_active Ceased
- 2003-10-14 NZ NZ566205A patent/NZ566205A/en not_active IP Right Cessation
- 2003-10-14 NZ NZ539311A patent/NZ539311A/en not_active IP Right Cessation
- 2003-10-14 BR BR0314512-3A patent/BR0314512A/pt active Search and Examination
- 2003-10-14 MX MXPA05003857A patent/MXPA05003857A/es active IP Right Grant
-
2005
- 2005-03-28 IL IL167706A patent/IL167706A/en not_active IP Right Cessation
- 2005-04-14 ZA ZA200503039A patent/ZA200503039B/en unknown
- 2005-05-10 NO NO20052276A patent/NO333932B1/no not_active IP Right Cessation
-
2006
- 2006-01-06 HK HK06100304.5A patent/HK1082761B/zh not_active IP Right Cessation
- 2006-05-26 HK HK06106108.0A patent/HK1086297A1/xx not_active IP Right Cessation
- 2006-09-15 US US11/521,412 patent/US7807444B2/en not_active Expired - Fee Related
-
2007
- 2007-10-30 US US11/978,617 patent/US20090252713A1/en not_active Abandoned
-
2009
- 2009-04-09 AU AU2009201405A patent/AU2009201405A1/en not_active Abandoned
- 2009-10-22 JP JP2009243117A patent/JP4750203B2/ja not_active Expired - Fee Related
-
2011
- 2011-11-24 CY CY20111101155T patent/CY1112110T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE521695T1 (de) | Zirkuläres dna-molekül mit einem konditionalen replikationsursprung, verfahren zur herstellung davon und ihre verwendung in der gentherapie | |
ATE500331T1 (de) | Verfahren zur gleichzeitigen herstellung von multiplen proteinen; vektoren und zellen, die hierfür verwendung finden | |
ATE475708T1 (de) | Fusionskonstrukte und deren verwendung zur produktion von antikörpern mit erhöhter fc rezeptor bindungsaffinität und effektorfunktion | |
WO2006042158A3 (en) | Methods and compositions for improving recombinant protein production | |
ATE490309T1 (de) | Mutante e. coli-appa-phytaseenzyme und natürliche varianten davon, solche phytaseenzyme codierende nukleinsäuren, diese enthaltende vektoren und wirtszellen und verfahren zur herstellung und verwendung davon | |
BR0011499A (pt) | Moléculas de ácido nucléico oriundas de plantas e células de,planta transgênicas de trigo e o seu uso para a produção de amido modificado | |
WO2002078524A3 (en) | Translational profiling | |
HUP9900018A1 (hu) | Cirkuláris DNS-molekula feltételes replikációs origóval, eljárás előállítására és génterápiában való felhasználására | |
ATE414162T1 (de) | Verfahren und materialien zur herstellung von glucosamin | |
DE69920747D1 (de) | Methode zur herstellung von rekombinanten zellen | |
EA200701023A1 (ru) | Отбор клеток-хозяев, экспрессирующих белок на высоких уровнях | |
WO2003093469A3 (en) | Methods for delivering nucleic acid molecules into cells and assessment thereof | |
SI1809750T1 (sl) | Izbira gostiteljskih celic, ki imajo visok nivo izraĹľanja proteina | |
DE69935978D1 (de) | Kulturmedium zur kultivierung tierischer zellen und verfahren zur herstellung von proteinen durch dessen verwendung | |
WO2004053137A3 (en) | Method for protein production | |
ATE310085T1 (de) | Cyclin-e2 proteine und dafür kodierende gene | |
WO2004005475A3 (en) | Purified and isolated heparan sulfate 3-o-sulfotransferase isoform 5 nucleic acids and polypeptides and therapeutic and screening methods using same | |
ATE446384T1 (de) | Verfahren zur amplifikation von nukleinsäuren mittels promotor-templates | |
WO2004013333A3 (de) | Revertierung der negativ-selektiven wirkung von negativen markerproteinen als selektionsverfahren | |
DK1340085T3 (da) | Assay til direkte detektion af en biologisk celle i en legemsvæskepröve | |
ATE434043T1 (de) | Verfahren zur herstellung transkriptionsaktiver linearer dna-moleküle und deren verwendung auf arrays | |
ATE403730T1 (de) | Gene, die fuer kohlenstoffmetabolismus- und energieproduktions-proteine codieren | |
WO2006091892A3 (en) | Methods of producing recombinant proteins | |
ATE547427T1 (de) | Verfahren zur rekombinanten herstellung von ribonukleoproteinen | |
WO2004096999A3 (en) | In vitro translation system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1549735 Country of ref document: EP |